Page 22 - Genevant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Here, in our final post, we provide an analysis of the current landscape and offer conclusions. Moderna, BioNTech and CureVac –Leading Pioneers The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manufacture, development, and commercialization of mRNA-based products. Moderna and BioNTech (with Pfize...

To embed, copy and paste the code into your website or blog: In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss certain issues relating to lipid nanoparticle (LNP) delivery technology. More mRNA Market Players Translate Bio Translate Bio, Inc. (NASDAQ: TBIO) is headquartered in Lexington, MA, and as of April 2021, has a market capitalization of over $1.3 billion. According to its website, Translate BIO’s mRNA product pipel...

BioNTech, Moderna shore up supplies of key COVID-19 vaccine ingredients FILE PHOTO: A nurse fills a syringe with a second dose of the Pfizer-BioNTech COVID-19 vaccine, as the coronavirus disease (COVID-19) outbreak continues, at Enfermera Isabel Zendal new pandemic hospital in Madrid, Spain, February 4, 2021. REUTERS/Sergio Perez/File Photo reuters_tickers This content was published on February 12, 2021 - 13:29 February 12, 2021 - 13:29 By Allison Martell, Ludwig Burger and Chad Terhune (Reuters) - Vaccine makers are shoring up their supply of a critical raw material in "messenger RNA" vaccin...

Vaccine makers are shoring up their supply of a critical raw material in "messenger RNA" vaccines: the lipid molecules that help deliver the genetic RNA material into cells.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine Gritstone Oncology, IncJanuary 20, 2021 GMT — Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 — — Agreement is the second between the parties since October 2020 — EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 ...